JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB231078

Anti-C3b / iC3b antibody [7C12]

Be the first to review this product! Submit a review

|

(5 Publications)

Mouse Monoclonal C3 antibody. Suitable for ELISA, WB and reacts with Human samples. Cited in 5 publications.

View Alternative Names

CPAMD1, C3, Complement C3, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1

3 Images
ELISA - Anti-C3b / iC3b antibody [7C12] (AB231078)
  • ELISA

Unknown

ELISA - Anti-C3b / iC3b antibody [7C12] (AB231078)

96-well microtitre plates were coated overnight at 4°C with recombinant human C3, C3b, iC3b, and Factor H proteins, in duplicate at a concentration of 1μg/mL. Plates were blocked with 1% BSA in PBS-T (0.1% Tween®) for 1 hour before incubation with a 10-step 4x serial dilution of ab231078 from 10μg/mL for 1 hour at room temperature. Antibody binding was detected with Goat Anti-Mouse IgG H&L (HRP) (ab6789) secondary antibody at a 1 in 10000 dilution for 1 hour at room temperature. Plates were incubated with TMB ELISA substrate for 7 minutes prior to being stopped with Stop solution and absorbance measured at 450nm.

Western blot - Anti-C3b / iC3b antibody [7C12] (AB231078)
  • WB

Supplier Data

Western blot - Anti-C3b / iC3b antibody [7C12] (AB231078)

This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 55 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 5% milk before ab231078 and ab181602 (Rabbit anti GAPDH) were incubated overnight at 4°C at a 1ug/ml concentration and 1/10000 dilution respectively. Antibody binding was detected using Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-C3b / iC3b antibody [7C12] (ab231078)

Lane 1:

Human serum diluted 1/100 at 5 µL

Lane 2:

Human plasma diluted 1/100 at 5 µL

Lane 3:

Human liver whole tissue lysate at 20 µg

Predicted band size: 187 kDa

Observed band size: 42 kDa

false

Western blot - Anti-C3b / iC3b antibody [7C12] (AB231078)
  • WB

Lab

Western blot - Anti-C3b / iC3b antibody [7C12] (AB231078)

This blot was produced using a 4-12% Bis-tris under the MOPS buffer system. The gel was run at 200V for 55 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 5% milk before being incubated with ab231078 overnight at 4°C at 1ug/ml. Antibody binding was detected using Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (ab216772) at 1/20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-C3b / iC3b antibody [7C12] (ab231078) at 1 µg/mL

Lane 1:

Human Sera diluted 1/1000 at 10 µL

Lane 2:

Purified C3 Protein at 0.1 µg

Lane 3:

Purified C3b Protein at 0.1 µg

Lane 4:

Purified iC3b Protein at 0.1 µg

Predicted band size: 187 kDa

Observed band size: 110 kDa,125 kDa,43 kDa,78 kDa

false

  • Carrier free

    Anti-C3b / iC3b antibody [7C12] - BSA and Azide free

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

7C12

Isotype

IgG1

Light chain type

kappa

Carrier free

No

Reacts with

Human

Applications

WB, ELISA

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ELISA" : {"fullname" : "ELISA", "shortname":"ELISA"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "ELISA-species-checked": "testedAndGuaranteed", "ELISA-species-dilution-info": "10 µg/mL", "ELISA-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1 µg/mL", "WB-species-notes": "<p></p>" } } }

Product details

Want a custom formulation?
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com

Properties and storage information

Form
Liquid
Purification technique
Affinity purification
Storage buffer
Preservative: 0.02% Sodium azide Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

C3b protein also known as complement component 3b plays a significant role in the immune system aiding in the clearance of pathogens. It is a large glycoprotein with a mass of approximately 180 kDa. C3b is expressed mainly in the liver and released into the bloodstream as part of the complement system. Upon activation from its precursor C3 it becomes involved in opsonization enhancing the phagocytosis of pathogens by marking them for destruction by immune cells.
Biological function summary

C3b acts as a critical mediator in the immune system by forming complexes with other complement proteins. It is part of the alternative and classical pathways of the complement system. C3b can also convert itself into iC3b after cleavage by factor I and iC3b continues to facilitate phagocytosis but with reduced ability to promote further complement activation. This conversion ensures homeostasis and regulation preventing overactivation of the immune system.

Pathways

C3b participates in both the classical and alternative pathways of the complement system. It associates with proteins such as factor B and factor D to form the C3bBb complex in the alternative pathway acting as a C3 convertase that amplifies response. In the classical pathway C3b enhances the activity of C5 convertase facilitating the formation of the membrane attack complex. These pathways are vital in maintaining immune surveillance and response to infections.

Dysfunction or dysregulation of C3b activity links to autoimmune diseases and infectious diseases. For example atypical hemolytic uremic syndrome (aHUS) involves uncontrolled complement activation due to mutations affecting proteins like C3b. In such conditions C3b and related proteins such as factor H become therapeutic targets to modulate the complement system's overactivation. Studying the role of C3b in these diseases provides insight into potential interventions and novel treatments to manage complement-related pathologies.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Precursor of non-enzymatic components of the classical, alternative, lectin and GZMK complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system.. Complement C3b. Non-enzymatic component of C5 convertase (PubMed : 28264884, PubMed : 31507604, PubMed : 3653927, PubMed : 3897448). Generated following cleavage by C3 convertase, it covalently attaches to the surface of pathogens, where it acts as an opsonin that marks the surface of antigens for removal (PubMed : 28264884, PubMed : 31507604, PubMed : 3653927, PubMed : 3897448, PubMed : 833545, PubMed : 8349625). Complement C3b binds covalently via its reactive thioester, to cell surface carbohydrates or immune aggregates (PubMed : 6903192). Together with complement C4b, it then recruits the serine protease complement C2b to form the C5 convertase, which cleaves and activate C5, the next component of the complement pathways (PubMed : 12878586, PubMed : 18204047, PubMed : 2387864). In the alternative complement pathway, recruits the serine protease CFB to form the C5 convertase that cleaves and activates C5 (PubMed : 624565, PubMed : 6554279).. C3a anaphylatoxin. Mediator of local inflammatory process released following cleavage by C3 convertase (PubMed : 6968751, PubMed : 37169960, PubMed : 37852260). Acts by binding to its receptor, C3AR1, activating G protein-coupled receptor signaling, promoting the phosphorylation, ARRB2-mediated internalization and endocytosis of C3AR1 (PubMed : 8702752, PubMed : 37169960, PubMed : 37852260). C3a anaphylatoxin stimulates the activation of immune cells such as mast cells and basophilic leukocytes to release inflammation agents, such as cytokines, chemokines and histamine, which promote inflammation development (PubMed : 23383423). Also acts as potent chemoattractant for the migration of macrophages and neutrophils to the inflamed tissues, resulting in neutralization of the inflammatory triggers by multiple ways, such as phagocytosis and generation of reactive oxidants (PubMed : 23383423, PubMed : 342601, PubMed : 5778786).. Acylation stimulating protein. Adipogenic hormone that stimulates triglyceride synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial triglyceride clearance (PubMed : 10432298, PubMed : 15833747, PubMed : 16333141, PubMed : 19615750, PubMed : 2909530, PubMed : 8376604, PubMed : 9059512). Appears to stimulate triglyceride synthesis via activation of the PLC, MAPK and AKT signaling pathways (PubMed : 16333141). Acts by binding to its receptor, C5AR2, activating G protein-coupled receptor signaling, promoting the phosphorylation, ARRB2-mediated internalization and endocytosis of C5AR2 (PubMed : 11773063, PubMed : 12540846, PubMed : 19615750). In contrast to C3a anaphylatoxin peptide, does not show pro-inflammatory activity (PubMed : 37852260).. C3-beta-c. Acts as a chemoattractant for neutrophils in chronic inflammation.
See full target information C3

Publications (5)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in oncology 15:1531420 PubMed40519291

2025

Metformin inhibits the proliferation of hepatocellular carcinoma cells through inducing ferroptosis analyzed by phosphoproteomics.

Applications

Unspecified application

Species

Unspecified reactive species

Jihan Sun,Xi Yu,Yuying Shan,Manyun Dai,Andrea Gaucherot,Caide Lu,Shuqi Mao

Blood 115:2283-91 PubMed20068220

2010

A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement.

Applications

Unspecified application

Species

Unspecified reactive species

Margaret A Lindorfer,Andrew W Pawluczkowycz,Elizabeth M Peek,Kimberly Hickman,Ronald P Taylor,Charles J Parker

Journal of immunology (Baltimore, Md. : 1950) 172:3280-8 PubMed14978136

2004

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.

Applications

Unspecified application

Species

Unspecified reactive species

Adam D Kennedy,Paul V Beum,Michael D Solga,David J DiLillo,Margaret A Lindorfer,Charles E Hess,John J Densmore,Michael E Williams,Ronald P Taylor

Blood 101:1071-9 PubMed12393727

2002

An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab.

Applications

Unspecified application

Species

Unspecified reactive species

Adam D Kennedy,Michael D Solga,Theodore A Schuman,Amos W Chi,Margaret A Lindorfer,William M Sutherland,Patricia L Foley,Ronald P Taylor

Journal of immunological methods 120:241-9 PubMed2786912

1989

Preparation of monoclonal antibodies to C3b by immunization with C3b(i)-sepharose.

Applications

Unspecified application

Species

Unspecified reactive species

L Tosic,W M Sutherland,J Kurek,J C Edberg,R P Taylor
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com